Flerie

AnaCardio is a clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of heart failure. The company’s therapeutic drugs aim to enhance the contractility of the heart muscle through a unique mechanism involving a therapeutic peptide. This approach is designed to avoid common adverse effects associated with heart treatments, such as tachycardia, arrhythmia, ischemia, and hypotension. By improving cardiac output safely, AnaCardio's therapies have the potential to enhance organ function, boost quality of life, increase functional capacity, and reduce the risk of hospitalization and mortality in patients with heart failure.

Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.

Synerkine Pharma is engaged in the development of novel fusion proteins aimed at treating inflammatory, neuropathic, and osteoarthritic pain. The company's innovative protein targets key regulatory mechanisms associated with various forms of chronic pain, offering unique properties that help normalize pain and inhibit inflammation. This approach enables patients to access effective pharmaceutical solutions designed to reduce pain across multiple pre-clinical models.

Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions utilizing synthetic biology. The company’s product pipeline includes Vaxonella, which is designed to enhance immune responses through its unique delivery method involving micro fold cells in the small intestine. Prokarium is also working on vaccines targeting Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. With a focus on microbial immunotherapy, Prokarium aims to revolutionize cancer treatment, particularly in bladder cancer, by creating immune-driven, long-lasting antitumor effects. Founded in 2007, Prokarium is committed to advancing the field of immuno-oncology through innovative approaches that harness the power of synthetic biology.

Lipum AB, based in Umeå, Sweden, is a clinical-stage biopharmaceutical company focused on developing novel treatments for chronic inflammatory diseases. Its lead candidate, SOL-116, is a first-in-class, humanized antibody designed to block a previously overlooked target molecule (BSSL) of the immune system, offering a new mechanism of action for treating conditions like rheumatoid arthritis and juvenile idiopathic arthritis. Lipum aims to alleviate symptoms and reduce the need for corticosteroids and immunosuppressants, potentially improving the quality of life for millions of patients.

Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.

AnaCardio is a clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of heart failure. The company’s therapeutic drugs aim to enhance the contractility of the heart muscle through a unique mechanism involving a therapeutic peptide. This approach is designed to avoid common adverse effects associated with heart treatments, such as tachycardia, arrhythmia, ischemia, and hypotension. By improving cardiac output safely, AnaCardio's therapies have the potential to enhance organ function, boost quality of life, increase functional capacity, and reduce the risk of hospitalization and mortality in patients with heart failure.

XNK Therapeutics is a clinical-stage biotechnology company based in Stockholm, Sweden, specializing in immunotherapy for cancer prevention and treatment. The company develops innovative therapies centered on autologous natural killer (NK) cells utilizing its proprietary technology platform. This platform enables the creation of NK cell-based products that are particularly effective in targeting cancers, especially in scenarios where allogeneic cell therapies may not be suitable. XNK Therapeutics aims to play a pivotal role in advancing cancer treatment strategies through its leading investigational drug candidates and established expertise in the development and manufacture of these specialized therapies.

Geneos Therapeutics, Inc. is focused on producing and developing neoantigen-targeting cancer immunotherapies. Founded in 2016 and headquartered in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are tailored to the unique tumor mutations of each patient. This innovative approach involves identifying relevant neoantigen targets from individual tumors, allowing for the development of novel treatments aimed at providing targeted immunotherapies for various types of cancer. By offering these customized solutions, Geneos seeks to enhance the effectiveness of cancer treatment and improve outcomes for patients.

Strike Pharma specializes in personalized cancer treatment through its proprietary Adaptable Drug Affinity Conjugate (ADAC) technology. The company employs an antibody-based approach tailored to the genetic profile of each patient's tumor, effectively targeting and destroying cancer cells while sparing healthy cells. This method not only aims to enhance the efficacy of treatment but also strives to reduce the risk of side effects, making it a more affordable option for patients. By focusing on scalable personalized immunotherapy, Strike Pharma seeks to improve outcomes for individuals facing cancer.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.

Synerkine Pharma is engaged in the development of novel fusion proteins aimed at treating inflammatory, neuropathic, and osteoarthritic pain. The company's innovative protein targets key regulatory mechanisms associated with various forms of chronic pain, offering unique properties that help normalize pain and inhibit inflammation. This approach enables patients to access effective pharmaceutical solutions designed to reduce pain across multiple pre-clinical models.

Amarna Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, focused on developing viral vector-based therapies and vaccines. Established in 2008, the company utilizes its proprietary SVac platform, which is designed for next-generation gene and immune therapies. Amarna's research targets a variety of conditions, including allergies, genetic disorders, cancer, and autoimmune diseases. The company collaborates with prominent organizations such as Fundación Medina and Memorial Sloan-Kettering Cancer Center to enhance its capabilities in virology, vector production, and immunology. By fostering a global consortium of experts, Amarna aims to create innovative interventions that can significantly improve patient outcomes and reduce healthcare costs. Its goal is to become a leading entity in gene therapy, offering effective and safe drug delivery solutions for both rare and common diseases.

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory disorders by enhancing epithelial barrier integrity. This barrier is crucial for the proper functioning of human skin, lung tissue, the intestinal tract, and genitalia. Disruption of this barrier is linked to chronic inflammation and various diseases. The company is creating a proprietary portfolio of orally available macrolide drug candidates, which aim to serve as first-in-class disease-modifying therapeutics for chronic respiratory conditions and other significant unmet medical needs. EpiEndo's lead candidate, EP395, is designed to be the first oral, non-antibiotic macrolide that strengthens barriers and reduces inflammation in patients with chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases.

KAHR Medical Ltd. is an immuno-oncology drug development company based in Jerusalem, Israel, founded in 2005. The company focuses on creating fusion protein pharmaceuticals aimed at treating cancer and autoimmune diseases. KAHR develops innovative drugs such as DSP105 and DSP106, which facilitate T-cell mediated tumor destruction, and DSP107, which targets CD47 tumors to activate phagocytes while delivering an immune costimulatory signal. Utilizing a unique platform of multifunctional immuno-recruitment proteins, KAHR's technology aims to enhance immune system recognition of cancer cells, thereby addressing the challenge of cancer evasion. This approach represents a significant advancement in protein-based pharmaceuticals, expanding treatment options for patients facing these serious health conditions.

Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions utilizing synthetic biology. The company’s product pipeline includes Vaxonella, which is designed to enhance immune responses through its unique delivery method involving micro fold cells in the small intestine. Prokarium is also working on vaccines targeting Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. With a focus on microbial immunotherapy, Prokarium aims to revolutionize cancer treatment, particularly in bladder cancer, by creating immune-driven, long-lasting antitumor effects. Founded in 2007, Prokarium is committed to advancing the field of immuno-oncology through innovative approaches that harness the power of synthetic biology.

KAHR Medical Ltd. is an immuno-oncology drug development company based in Jerusalem, Israel, founded in 2005. The company focuses on creating fusion protein pharmaceuticals aimed at treating cancer and autoimmune diseases. KAHR develops innovative drugs such as DSP105 and DSP106, which facilitate T-cell mediated tumor destruction, and DSP107, which targets CD47 tumors to activate phagocytes while delivering an immune costimulatory signal. Utilizing a unique platform of multifunctional immuno-recruitment proteins, KAHR's technology aims to enhance immune system recognition of cancer cells, thereby addressing the challenge of cancer evasion. This approach represents a significant advancement in protein-based pharmaceuticals, expanding treatment options for patients facing these serious health conditions.

Amarna Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, focused on developing viral vector-based therapies and vaccines. Established in 2008, the company utilizes its proprietary SVac platform, which is designed for next-generation gene and immune therapies. Amarna's research targets a variety of conditions, including allergies, genetic disorders, cancer, and autoimmune diseases. The company collaborates with prominent organizations such as Fundación Medina and Memorial Sloan-Kettering Cancer Center to enhance its capabilities in virology, vector production, and immunology. By fostering a global consortium of experts, Amarna aims to create innovative interventions that can significantly improve patient outcomes and reduce healthcare costs. Its goal is to become a leading entity in gene therapy, offering effective and safe drug delivery solutions for both rare and common diseases.

Empros Pharma AB is a Swedish company founded in 2013, focused on developing pharmaceutical treatments for overweight and obesity. The company's primary product, EMP16, is an oral drug that works by delaying food digestion and absorption in the small intestine, thereby regulating food intake. Empros Pharma addresses the growing concerns related to obesity, particularly among children and adolescents, and is positioned to adapt to changes in reimbursement systems for obesity treatments. Through its innovative approach, the company aims to enhance healthcare options and improve the quality of life for individuals struggling with weight-related issues.

Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions utilizing synthetic biology. The company’s product pipeline includes Vaxonella, which is designed to enhance immune responses through its unique delivery method involving micro fold cells in the small intestine. Prokarium is also working on vaccines targeting Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. With a focus on microbial immunotherapy, Prokarium aims to revolutionize cancer treatment, particularly in bladder cancer, by creating immune-driven, long-lasting antitumor effects. Founded in 2007, Prokarium is committed to advancing the field of immuno-oncology through innovative approaches that harness the power of synthetic biology.

OxThera AB is a biopharmaceutical company focused on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. Founded in 2005 and based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee, OxThera manufactures two main products: Oxabact and Oxazyme. Oxabact is an orally administered composition of live bacteria designed to enhance the removal of oxalate produced by the body, while Oxazyme is a non-systemic oral drug that contains recombinant oxalate decarboxylase, aimed at treating dietary hyperoxaluria and preventing kidney stones. The company holds worldwide patents for its innovative therapies and has received Orphan Drug designations for Oxabact in both Europe and the United States. Through its advanced biotherapy technologies, OxThera aims to improve kidney health and preserve organ function in patients affected by hyperoxaluria.

KAHR Medical Ltd. is an immuno-oncology drug development company based in Jerusalem, Israel, founded in 2005. The company focuses on creating fusion protein pharmaceuticals aimed at treating cancer and autoimmune diseases. KAHR develops innovative drugs such as DSP105 and DSP106, which facilitate T-cell mediated tumor destruction, and DSP107, which targets CD47 tumors to activate phagocytes while delivering an immune costimulatory signal. Utilizing a unique platform of multifunctional immuno-recruitment proteins, KAHR's technology aims to enhance immune system recognition of cancer cells, thereby addressing the challenge of cancer evasion. This approach represents a significant advancement in protein-based pharmaceuticals, expanding treatment options for patients facing these serious health conditions.

Empros Pharma AB is a Swedish company founded in 2013, focused on developing pharmaceutical treatments for overweight and obesity. The company's primary product, EMP16, is an oral drug that works by delaying food digestion and absorption in the small intestine, thereby regulating food intake. Empros Pharma addresses the growing concerns related to obesity, particularly among children and adolescents, and is positioned to adapt to changes in reimbursement systems for obesity treatments. Through its innovative approach, the company aims to enhance healthcare options and improve the quality of life for individuals struggling with weight-related issues.

KAHR Medical Ltd. is an immuno-oncology drug development company based in Jerusalem, Israel, founded in 2005. The company focuses on creating fusion protein pharmaceuticals aimed at treating cancer and autoimmune diseases. KAHR develops innovative drugs such as DSP105 and DSP106, which facilitate T-cell mediated tumor destruction, and DSP107, which targets CD47 tumors to activate phagocytes while delivering an immune costimulatory signal. Utilizing a unique platform of multifunctional immuno-recruitment proteins, KAHR's technology aims to enhance immune system recognition of cancer cells, thereby addressing the challenge of cancer evasion. This approach represents a significant advancement in protein-based pharmaceuticals, expanding treatment options for patients facing these serious health conditions.

Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions utilizing synthetic biology. The company’s product pipeline includes Vaxonella, which is designed to enhance immune responses through its unique delivery method involving micro fold cells in the small intestine. Prokarium is also working on vaccines targeting Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. With a focus on microbial immunotherapy, Prokarium aims to revolutionize cancer treatment, particularly in bladder cancer, by creating immune-driven, long-lasting antitumor effects. Founded in 2007, Prokarium is committed to advancing the field of immuno-oncology through innovative approaches that harness the power of synthetic biology.